Trelegy Ellipta
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Trelegy Ellipta ([fluticasone furoate + vilanterol + umeclidinium bromide]; GlaxoSmithKline) is a fixed triple combination inhaled corticosteroid/long-acting beta 2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) therapy. The product contains the same ICS/LABA components as Breo ([fluticasone furoate + vilanterol]; GlaxoSmithKline/Innoviva), plus a LAMA component, umeclidinium bromide.
GlaxoSmithKline received approval for Trelegy Ellipta in chronic obstructive pulmonary disease in Q3 2017, and is currently evaluating the drug in asthma patients whose symptoms are inadequately controlled by ICS/LABA therapies.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Trelegy Ellipta : Chronic obstructive pulmonary disease (COPD)
18 Trelegy Ellipta : Asthma
LIST OF FIGURES
11 Figure 1: Trelegy Ellipta for COPD – SWOT analysis
12 Figure 2: Datamonitor Healthcare’s drug assessment summary of Trelegy Ellipta for COPD
13 Figure 3: Datamonitor Healthcare’s drug assessment summary of Trelegy Ellipta for COPD
15 Figure 4: Trelegy Ellipta sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
22 Figure 5: Trelegy Ellipta for asthma – SWOT analysis
23 Figure 6: Datamonitor Healthcare’s drug assessment summary of Trelegy Ellipta in asthma
24 Figure 7: Datamonitor Healthcare’s drug assessment summary of Trelegy Ellipta in asthma
27 Figure 8: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Trelegy Ellipta drug profile
7 Table 2: Trelegy Ellipta Phase III data in COPD
10 Table 3: Trelegy Ellipta Phase III trial in COPD
16 Table 4: Trelegy Ellipta sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
18 Table 5: Trelegy Ellipta drug profile
20 Table 6: Trelegy Ellipta Phase III trials in asthma
28 Table 7: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Breo Ellipta 
Sign up to the